Spatially Resolved Epithelial States Delineate Immunosuppressive Niches of Impaired Myeloid Antigen Presentation in PDAC

Bulk transcriptomic classifiers stratify pancreatic ductal adenocarcinoma (PDAC) into classical and basal-like subtypes with prognostic and therapeutic relevance, yet increasing evidence indicates tha...

biorxiv.org

Prohaptoglobin Promotes Pancreatic Cancer Progression by sustaining YAP Activity

Background & Aims: Prohaptoglobin (proHp), a precursor of haptoglobin (Hp), has recently emerged as a cancer-associated biomarker, but its functional role in pancreatic cancer remains unclear. We inve...

biorxiv.org

Metabolic plasticity underlies ferroptosis resistance driven by mutant p53 in pancreatic ductal adenocarcinoma - Molecular Cancer

Background Pancreatic ductal adenocarcinoma (PDAC) is an aggressive malignancy characterized by late diagnosis, rapid progression, and resistance to conventional therapies. Mutations in the tumor supp...

link.springer.com

LSD1-GLS2 axis drives subtype-specific chemoresistance in pancreatic cancer through glutaminolysis reprogramming - Cell Death & Disease

Cell Death & Disease - LSD1-GLS2 axis drives subtype-specific chemoresistance in pancreatic cancer through glutaminolysis reprogramming

nature.com

Epithelial FOXP3: The Silent Spark That Lights the Fire of Pancreatic Cancer

For decades, we have viewed pancreatic fibrosis as a passive scar—the end-stage wreckage of chronic inflammation or a late accomplice of growing tumor…

sciencedirect.com

Cell‐Selective Delivery of RIBOTACs via an Anti‐EGFR Nanobody for Pancreatic Cancer Treatment

This study introduces an innovative strategy for the tumor-selective catalytic degradation of oncogenic non-coding RNA by interfacing a ribonuclease-recruiting small molecule (RIBOTAC) with an EGFR-t...

advanced.onlinelibrary.wiley.com

onlinelibrary.wiley.com

3D Epigenomic Remodelling Mediated by Foxa1 Drives Gemcitabine Resistance in Pancreatic Cancer

Gemcitabine remains a cornerstone treatment for pancreatic ductal adenocarcinoma (PDAC), yet the emergence of resistance constitutes a major clinical …

sciencedirect.com

Validate User

aacrjournals.org

sciencedirect.com

Concurrent Stereotactic Body Radiation Therapy and KRAS Inhibition Synergistically Improve Pre-clinical Pancreatic Cancer Treatment

Pancreatic ductal adenocarcinoma (PDAC) is one of the most challenging cancers to treat due to the dismal survival rate, poor post-treatment outcome and profound resistance to a wide range of therapie...

biorxiv.org

Multi-omics network reconstruction with collaborative graphical lasso

AbstractMotivation. In recent years, the availability of multi-omics data has increased substantially. Multi-omics data integration methods mainly aim to l

academic.oup.com

sciencedirect.com

Prognostic host phenotypes based on body composition and systemic inflammation predict survival in patients with resected pancreatic and periampullary cancer

Most present-day survival-models of patients with cancer do not account for tumor-host interactions. We hypothesized that host phenotypes based on sys…

sciencedirect.com

ESRP1-regulated DNMT3B isoform switching determines the malignant potential of pancreatic cancer - Oncogene

Oncogene - ESRP1-regulated DNMT3B isoform switching determines the malignant potential of pancreatic cancer

nature.com

Targeting of solute carrier family 1 member 1 that links metabolic reprogramming and ferroptosis sensitivity in pancreatic ductal adenocarcinoma - Oncogene

Pancreatic cancer is among the most lethal forms of cancer, underscoring an urgent need for novel therapeutic approaches. The present study examined a protein known as SLC1A1, which facilitates the re...

nature.com

WT1‐Targeted Oral Bifidobacterium longum Vaccine Enhances Checkpoint Blockade Efficacy in Pancreatic Cancer

Oral WT1-targeted Bifidobacterium longum vaccine promotes WT1-associated cellular immunity and enhances anti-PD-1/anti-CTLA-4 efficacy in pancreatic cancer.

advanced.onlinelibrary.wiley.com

KRAS-G12D inhibitor HRS-4642 plus chemotherapy in advanced KRASG12D-mutant pancreatic cancer: a phase 1b/2 trial - Nature Medicine

In phase 1b/2 trial, the treatment of patients with metastatic KRASG12D-mutant pancreatic cancer, the intravenously delivered KRAS-G12D inhibitor HRS-4642 plus nab-paclitaxel and gemcitabine led to en...

nature.com

Spatial immune architecture and tumor lineage programs jointly shape clinical outcomes in advanced pancreatic ductal adenocarcinoma

Pancreatic ductal adenocarcinoma (PDAC) exhibits extensive molecular and microenvironmental heterogeneity, yet how tumor lineage states interact with spatial immune organization in advanced disease re...

biorxiv.org

Vertical inhibition of the autophagy pathway impairs growth and enhances sensitivity to mTORC1 inhibition in pancreatic ductal adenocarcinoma

Pancreatic ductal adenocarcinoma (PDAC) is dependent on autophagy for growth. Chloroquine/Hydroxychloroquine (CQ/HCQ), the sole FDA-approved autophagy inhibitors, have shown limited clinical efficacy ...

biorxiv.org

PNAS

Proceedings of the National Academy of Sciences (PNAS), a peer reviewed journal of the National Academy of Sciences (NAS) - an authoritative source of high-impact, original research that broadly spans...

pnas.org

Curso de Verano Cáncer de Páncreas - UFV

Desde los fundamentos Biológicos hasta las terapias emergentes, una inmersión completa en el cáncer de páncreas.

ufv.es

BioNeuralNet: a graph neural network based Multi-Omics network data analysis tool

AbstractSummary. Multi-omics data offer unprecedented insights into complex biological systems, yet their high dimensionality, sparsity, and intricate inte

academic.oup.com